Harrow earnings release, August 10, 2026

Harrow, Inc. (HROW) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Harrow

Announces Second Quarter 2026 Financial Results

Second

Quarter 2026 and Selected Highlights:

NASHVILLE,

Tenn., August 10, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2026. The Company also posted its second-quarter Letter to Stockholders and corporate presentation in the “Investors” section of its website at harrow.com. The Company encourages Harrow stockholders to review these documents, which provide additional details concerning the historical results and future expectations for the business.

“We spent the first half of 2026 building demand and positioning the business to achieve our 2026 and 2027 financial objectives. The second half of 2026 is about converting that demand into accelerating revenue growth and profitability,” said Mark L. Baum, Chairman and

Chief Executive Officer of Harrow. “Over the past six months, we expanded our commercial organization, strengthened our portfolio, improved pricing across key products, launched BYOOVIZ®, advanced multiple clinical programs, and announced the acquisition of TYRVAYA. VEVYE delivered record quarterly revenue while improving its underlying economics, and momentum continues to build, supported by our recent coverage win that went into effect August 1.

IHEEZO achieved the strongest commercial quarter in its history despite the loss of pass-through reimbursement, and TRIESENCE continued to generate exceptional demand growth – reinforcing our conviction that physician demand continues to strengthen across our portfolio.”

Baum continued, “As we enter the second half of the year, the business looks fundamentally different than it did just a few months ago:

IHEEZO’s pricing improvements are now in effect, IHEEZO’s channel inventories have normalized, VEVYE’s updated business rules have been fully implemented, BYOOVIZ has launched, and TYRVAYA is expected to join our portfolio later this year. Our commercial organization, which already expanded this year (and is now helping to fueling our growth), will increase further with the addition of experienced eye care sales professionals from Viatris. Together, these steps position us to convert the demand we’ve built into meaningful revenue growth and profitability. I believe Harrow has reached an important inflection point. The heavy lifting required to position the business for accelerated growth has largely been completed. The table is set. Now it’s about execution. Based on what we’re seeing across the business today, I remain confident in our ability to deliver our full-year guidance of $350 million to

$365 million in revenue and $80 million to $100 million in adjusted EBITDA.”

Key

Second Quarter Commercial Metrics

:

VEVYE:

IHEEZO:

TRIESENCE:

Business

Highlights

:

VEVYE

Expanded Coverage:

TYRVAYA

Acquisition:

-END-

BYOOVIZ

Launch:

Pipeline and Regulatory Highlights

:

Second

Quarter 2026 Financial Results

:

-END-

Conference

Call and Webcast

Harrow will host a conference call to discuss the results at 8:00 a.m. ET on Tuesday, August 11, 2026. Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.

To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, to access the call.

About

Harrow

Harrow,

Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on

LinkedIn.

Forward-Looking

Statements

Financial statements

Income Statement

For the Three Months Ended June 30, — Additional product-related revenue figures are reflected in the table below:

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025For the Six Months Ended June 30, – 2025
IHEEZO15,619,00022.0%18,336,00029.0%17,535,00015.0%23,558,00021.0%
VEVYE29,387,00042.0%18,641,00029.0%50,335,00044.0%40,156,00036.0%
Other branded products11,009,00016.0%5,212,0008.0%18,776,00016.0%6,169,0006.0%
Other revenues90,0000.0%85,0000.0%163,0000.0%171,0000.0%
Branded revenue, net56,105,00079.0%42,274,00066.0%86,809,00076.0%70,054,00063.0%
ImprimisRx revenue, net14,556,00021.0%21,468,00034.0%28,055,00024.0%41,519,00037.0%
Total revenues, net70,661,000100.0%63,742,000100.0%114,864,000100.0%111,573,000100.0%

Income Statement

For the Three Months Ended June 30, — Selected financial highlights regarding GAAP operating results for the three months and six months ended June 30, 2026 and 2025 are as follows:

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
Total revenues70,661,00063,742,000114,864,000111,573,000
Cost of sales20,298,00016,230,00037,456,00031,754,000
Gross profit50,363,00047,512,00077,408,00079,819,000
Selling, general and administrative53,298,00033,235,00096,528,00073,748,000
Research and development8,072,0002,868,00013,967,0005,894,000
Total operating expenses61,370,00036,103,000110,495,00079,642,000
(Loss) income from operations-11,007,00011,409,000-33,087,000177,000
Total other expense, net-6,263,000-6,414,000-11,760,000-12,962,000
Income tax expense25,000
Net (loss) income-17,270,0004,995,000-44,872,000-12,785,000
Net (loss) income per share:Basic-0.460.14-1.2-0.35
Net (loss) income per share:Diluted-0.460.13-1.2-0.35

Income Statement

For the Three Months Ended June 30, — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
Total revenues70,661,00063,742,000114,864,000111,573,000
Cost of sales20,298,00016,230,00037,456,00031,754,000
Gross profit50,363,00047,512,00077,408,00079,819,000
Selling, general and administrative53,298,00033,235,00096,528,00073,748,000
Research and development8,072,0002,868,00013,967,0005,894,000
Total operating expenses61,370,00036,103,000110,495,00079,642,000
(Loss) income from operations-11,007,00011,409,000-33,087,000177,000
Total other expense, net-6,263,000-6,414,000-11,760,000-12,962,000
Income tax expense25,000
Net (loss) income attributable to Harrow, Inc.-17,270,0004,995,000-44,872,000-12,785,000
Net (loss) income per share:Basic-0.460.14-1.2-0.35
Net (loss) income per share:Diluted-0.460.13-1.2-0.35

Balance Sheet

December 31, — CONDENSED CONSOLIDATED BALANCE SHEETS

June 30, – 2026December 31, – 2025
ASSETSCash and cash equivalents83,889,00072,927,000
ASSETSAll other current assets145,418,000138,823,000
ASSETSTotal current assets229,307,000211,750,000
ASSETSAll other assets187,509,000187,732,000
ASSETSTOTAL ASSETS416,816,000399,482,000
LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities102,171,00096,302,000
LIABILITIES AND STOCKHOLDERS’ EQUITYLoans payable, net of unamortized debt discount292,379,000243,184,000
LIABILITIES AND STOCKHOLDERS’ EQUITYAll other liabilities7,421,0007,905,000
LIABILITIES AND STOCKHOLDERS’ EQUITYTOTAL LIABILITIES401,971,000347,391,000
LIABILITIES AND STOCKHOLDERS’ EQUITYTOTAL STOCKHOLDERS’ EQUITY14,845,00052,091,000
LIABILITIES AND STOCKHOLDERS’ EQUITYTOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY416,816,000399,482,000
Full release

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward—looking statements.”

Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, or complete pending acquisitions on terms and in the timeframe expected, or at all, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks... (truncated)e pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; and physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q and other filings with the SEC. Such documents may be read free of charge on the SEC’s website at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking- statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact:

Mike

Biega, VP of Investor Relations and Communications mbiega@harrowinc.com

617-913-8890

-END-

HARROW,

INC.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Harrow earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.